Immunohistochemical expression of CD10 antigen in uterine adenosarcoma

Abstract

Uterine adenosarcoma (UAS) is microscopically characterized by a biphasic growth pattern. By definition, the epithelial component is benign, whereas the stromal component typically has the appearance of a low-grade sarcoma, usually an endometrial stromal sarcoma. CD10 acts by reducing cellular response to peptide hormones and is currently regarded as a specific marker for endometrial stromal tumors. In this international multicenter study, we further explored CD10 immunoreactivity in 30 UASs. We encountered CD10 positivity of the sarcomatous component in 18/20 (90%) of UASs, in five of eight (63%) of UASs with sarcomatous overgrowth as well as in both cases of recurrent UAS. The epithelial component stained negative in all cases. These findings suggest that CD10 can be used to differentiate UAS from cellular leiomyoma, or in case endometrial stromal cells exhibit muscle differentiation. Furthermore, CD10 positivity in recurrent UAS might guide the pathologist toward an endometrial stromal origin.

Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma: something old and something new

“…Even though desmin and SMA are usually expressed in ULMS, they have also been reported to be positive in 10–40% of ESS cases 28. Furthermore, positivity for CD10 ranged from 75% to 100% of ESS cases and from 0% to 60% of ULMS cases 15 19 29. Finally, even though h-caldesmon is very specific for ULMS, its Sen is only 50% 23.…”

Targeted genomic analysis of Müllerian adenosarcoma

“…Since the initial description [1], hundreds of uterine and extra-uterine MAs have been reported in the literature [2,3,6,11,12,29,30], and although many studies focused on immunohistochemical profiles in attempts to distinguish MA from other uterine tumours and to aid with prognostication [8,9,11,12,31], no sensitive or specific diagnostic or prognostic marker has been identified to date. In the present study of 18 MAs, we have performed next-generation sequencing of a large panel of well-established oncogenes and tumour suppressor genes.…”

“…and ER expression [8][9][10][11][12]. Some studies have found that p53 is aberrantly overexpressed in a few MAs with SO [11,15,16].…”

“…Immunohistochemically, CD10 is considered to be the most commonly recognized positive marker for MA [8][9][10][11][12][13][14]; however, WT-1, ER, and PR are also often…”

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Mullerian Adenosarcoma of the Female Genital Tract

“…3,4 IMMUNOHISTOCHEMISTRY In most adenosarcomas with a low-grade stromal component, the stromal element expresses estrogen receptor, progesterone receptor, CD10, and WT1 and is negative for P53, which is similar to the immunophenotype of ESSs. 3,15,16 The CD10 is the common acute lymphoblastic leukemia antigen and is a membrane glycoprotein that functions as a cell surface enzyme, which reduces cellular response to peptide hormones, and is a specific marker for ESSs, which is commonly the stromal component in adenosarcomas. 16 Amant et al 16 reported that 90% (18/20) of uterine adenosarcomas were CD10 positive, whereas 63% (5/8) adenosarcomas with sarcomatous overgrowth were CD10 positive.…”